GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • *Q2 EPS ex-items $1.23 vs $1.22 forecast. *Now sees 2014 EPS $4.50- $4.80 with Copaxone competition. TEL AVIV, July 31- Teva Pharmaceutical Industries raised its full-year profit forecast on Thursday after posting higher quarterly earnings that were due in part to the launch of several generic products in the United States.

  • JERUSALEM, July 31- Israeli industrialist Benny Landa said his campaign to improve corporate governance at Teva Pharmaceutical Industries was delivering results, despite losing a shareholder vote at the world's largest generic drugmaker.

  • Pfizer's 2Q profit sinks 79 pct but tops forecasts Tuesday, 29 Jul 2014 | 7:37 AM ET

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion- plus gain from a business spinoff.

  • However, the report from the Generic Pharmaceutical Association said REMS have been used to prevent generic drugmakers from getting branded medicine to test their own versions, which is required to win FDA approval.

  • U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.

  • TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.

  • A three-judge panel of the 6th U.S. Circuit Court of Appeals in Cincinnati rejected claims in 67 of the cases. Among the defendants in the various cases were Eli Lilly& Co, which won regulatory approval for Darvon in 1957 and Darvocet in 1972, and generic drug makers such as Mylan Inc and Teva Pharmaceutical Industries Ltd..

  • *European Commission declines to comment. BRUSSELS, June 19- EU antitrust regulators are set to fine French drugmaker Servier, Israel's Teva and several of their peers next month for blocking cheaper generic medicine, two people with knowledge of the matter said on Thursday.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • Chicago sues drugmakers, alleging painkiller risk Tuesday, 3 Jun 2014 | 10:37 AM ET

    Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.

  • Midday movers: Boeing, eBay, PetSmart & More Wednesday, 21 May 2014 | 1:02 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Wednesday's midday movers:

  • Midday movers: NFLX, PCLN, BIIB & more Thursday, 15 May 2014 | 12:23 PM ET
    NYSE exchange floor

    Take a look at some of Thursday's midday movers:

  • The case, in U.S. District Court in Washington, D.C., was dismissed on Wednesday as being premature because the FDA had not yet approved or rejected the applications for generic forms of the drug, Teva said.

  • May 15- Mylan Inc said a U.S. district court dismissed a case by Israeli drugmaker Teva Pharmaceutical Industries Ltd intended to block the U.S. health regulator from approving generic versions of Teva's multiple sclerosis drug Copaxone. U.S. generic drugmaker Mylan said it had intervened in the lawsuit in support of the U.S. Food and Drug Administration.

  • Why rivals are jealous of Pfizer's AstraZeneca deal Thursday, 1 May 2014 | 7:15 AM ET
    U.S. drugmaker Pfizer proposed buying AstraZeneca for about 58.8 billion pounds ($98.7 billion) in what would rank as the industry's biggest-ever takeover, surpassing Pfizer's $64 billion purchase of Wyeth in 2009.

    As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.

  • 'Weed' portfolios, but don't sell in May: Analysts Wednesday, 30 Apr 2014 | 6:56 PM ET
    Traders work on the floor of the New York Stock Exchange on April 30, 2014.

    Stocks closed out April with a bang and many watchers believe this is not the year to sell in May.

  • Teva's abuse-resistant painkiller succeeds in study Wednesday, 30 Apr 2014 | 8:33 AM ET

    April 30- Israel's Teva Pharmaceutical Industries Ltd said its experimental abuse-resistant pain drug significantly reduced patients' chronic low back pain in a late-stage trial. The drug is a twice-daily formulation of hydrocodone, which belongs to a powerful class of painkillers known as opioids that are also frequently abused.

  • April 28- Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. A similar lawsuit was announced Friday by Mylan Inc over generic drug marketing exclusivity for Celebrex.

  • Actavis sues FDA over generic Celebrex Monday, 28 Apr 2014 | 5:51 PM ET

    April 28- Actavis Plc on Monday said it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.

  • WASHINGTON, April 18- U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.